The results vaulted Nektar’s market value to over $1 billion amid expectations the drug might prove a challenger to widely ...

Nektar Therapeutics today announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of rezpegaldesleukin, a novel regulatory T-cell (Treg) biologic, in ...

Urea is a holy grail for dry, flaky, and itchy skin that not only helps with rough and cracked feet, but also helps ...

The newly public Evommune shared data showing that EVO301, an IL-18 targeting protein, cleared symptoms comparably to Regeneron and Sanofi’s mega-blockbuster in a mid-stage atopic dermatitis clinical ...

Initially, ear seeding was thought to be more of a minimalist piercing trend than a wellness therapy. With tiny beads, seeds, ...

IPO stock Evommune roughly doubled Tuesday on positive results for its intravenously infused eczema treatment.

Evommune (EVMN) stock surges as the company posts a mid-stage trial win for its experimental drug targeting atopic dermatitis ...

High-frequency wands use low-level electrical currents to kill acne-causing bacteria and reduce inflammation. At-home devices offer more convenience but less dramatic results than in-office ...

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology ...

Investing.com -- Evommune Inc. (NYSE:EVMN) stock soared 64% after the clinical-stage biotechnology company announced positive top-line results from its Phase 2a trial evaluating EVO301 in patients ...

Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies ...

An eczema drug from Nektar Therapeutics maintained skin responses in a one-year study, meeting and in some cases exceeding ...